Ассоциация экспрессии генов рецепторов фактора роста тромбоцитов альфа и бета (PDGFRA и PDGFRB) с биохимическим рецидивом рака предстательной железы после радикальной простатэктомии
https://doi.org/10.17650/1726-9776-2017-13-4-45-50
Аннотация
Проведен метаанализ результатов профилирования транскриптома образцов рака предстательной железы после радикальной простатэктомии у пациентов без метастатического поражения лимфатических узлов. Показана взаимосвязь экспрессии рецепторов фактора роста тромбоцитов альфа и бета (PDGFRA и PDGFRB), ассоциированных с лимфогенным метастазированием, с вероятностью и временем наступления биохимического рецидива.
Об авторах
М. Ю. ШкурниковРоссия
Максим Юрьевич Шкурников.
125284 Москва, 2-й Боткинский проезд, 3Б. Я. Алексеев
Россия
125284 Москва, 2-й Боткинский проезд, 3
Список литературы
1. Mottet N., Bellmunt J., Bolla M. et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis and local treatment with curative intent. Eur Urol 2017;71(4):618–29. DOI: 10.1016/j.eururo.2016.08.003. PMID: 27568654.
2. Smith J.A., Seaman J.P., Gleidman J.B., Middleton R.G. Pelvic lymph node metas
3. tasis from prostatic cancer: influence of tumor grade and stage in 452 consecutive patients. J Urol 1983;130(2):290–2. PMID: 6876275.
4. Schilling D., Hennenlotter J., Gakis G. et al. Prospective assessment of histological serial sectioning of pelvic lymph nodes in prostate cancer: a cost-benefit analysis. BJU Int 2012;110(6 Pt B):E166–71. DOI: 10.1111/j.1464-410X.2012.10928.x. PMID: 22314026.
5. Karalak A., Homcha-Em P. Occult axillary lymph node metastases discovered by serial section in node-negative breast cancer. J Med Assoc Thai 1999;82(10):1017–9. PMID: 10561965.
6. Hartveit E. Attenuated cells in breast stroma: the missing lymphatic system of the breast. Histopathology 1990;16(6):533–43. PMID: 2376396.
7. Pepper M.S., Tille J.C., Nisato R., Skobe M. Lymphangiogenesis and tumor metastasis. Cell Tissue Res 2003;314(1):167–77. DOI: 10.1007/s00441-003-0748-7. PMID: 12883995.
8. Joukov V., Pajusola K., Kaipainen A. et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996;15(2):1751. PMID: 8612600.
9. Stacker S.A., Caesar C., Baldwin M.E. et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001;7(2):186–91. DOI: 10.1038/84635. PMID: 11175849.
10. Skobe M., Hawighorst T., Jackson D.G. et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001;7(2):192–8. DOI: 10.1038/84643. PMID: 11175850.
11. Mandriota S.J., Jussila L., Jeltsch M. et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 2001;20(4):672–82. DOI: 10.1093/emboj/20.4.672. PMID: 11179212.
12. Tsurusaki T., Kanda S., Sakai H. et al. Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer 1999;80(1–2):309–13. DOI: 10.1038/sj.bjc.6690356. PMID: 10390013.
13. Wong S.Y., Haack H., Crowley D. et al. Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis. Cancer Res 2005;65(21):9789–98. DOI: 10.1158/0008-5472.CAN-05-0901. PMID: 16267000.
14. Galatenko V.V., Shkurnikov M.Y., Sama- tov T.R. et al. Highly informative marker sets consisting of genes with low individual de gree of differential expression. Sci Rep 2015;5:14967. DOI: 10.1038/srep14967. PMID: 26446398.
15. Mortensen M.M., Høyer S., Lynnerup A.S. et al. Expression profiling of prostate cancer tissue delineates genes associated with recurrence after prostatectomy. Sci Rep 2015;5(1):16018. DOI: 10.1038/srep16018. PMID: 26522007.
16. Nakagawa T., Kollmeyer T.M., Morlan B.W. et al. A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. PLoS One 2008;3(5):e2318. DOI: 10.1371/journal.pone.0002318. PMID: 18846227.
17. Briganti A., Suardi N., Capogrosso P. et al. Lymphatic spread of nodal metastases in high-risk prostate cancer: the ascending pathway from the pelvis to the retroperitoneum. Prostate 2012;72(2):186–92. DOI: 10.1002/pros.21420. PMID: 21538428.
18. Burton J.B., Priceman S.J., Sung J.L. et al. Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res 2008;68(19):7828–37. DOI: 10.1158/00085472.CAN-08-1488. PMID: 18829538.
19. Nathanson S.D. Insights into the mechanisms of lymph node metastasis. Cancer 2003;98(2):413–23. DOI: 10.1002/cncr.11464. PMID: 12872364.
20. Zhang H., Muders M.H., Li J. et al. Loss of NKX3.1 favors vascular endothelial growth factor-C expression in prostate cancer. Cancer Res 2008;68(21):8770–8. DOI: 10.1158/0008-5472.CAN-08-1912. PMID: 18974119.
21. Karlsson M.C., Gonzalez S.F., Welin J., Fuxe J. Epithelial-mesenchymal transition in cancer metastasis through the lymphatic system. Mol Oncol 2017;11(7):781–91. DOI: 10.1002/1878-0261.12092. PMID: 28590032.
22. Cortes C., Vapnik V. Support-Vector Networks. Machine Learning 1995;20(3):273–97.
23. Huang W., Fridman Y., Bonfil R.D. et al. A novel function for platelet-derived growth factor-D: induction of osteoclastic differentiation for intraosseous tumor growth. Oncogene 2012;31(42):4527–35. DOI: 10.1038/onc.2011.573. PMID: 22158043.
24. Hägglöf C., Hammarsten P., Josefsson A. et al. Stromal PDGFR-beta expression in prostate tumors and non-malignant prostate tissue predicts prostate cancer survival. PLoS One 2010;5(5):e10747. DOI: 10.1371/journal.pone.0010747. PMID: 20505768.
25. Rosenberg A., Mathew P. Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor. Expert Opin Investig Drugs 2013;22(6):787–94. DOI: 10.1517/13543784.2013.787409. PMID: 23540855.
26. Nordby Y., Richardsen E., Rakaee M. et al. High expression of PDGFR-β in prostate cancer stroma is independently associated with clinical and biochemical prostate cancer recurrence. Sci Rep 2017;7:43378. DOI: 10.1038/srep43378. PMID: 28233816.
27. Li Y., Cozzi P.J., Russell P.J. Promising tumor-associated antigens for future prostate cancer therapy. Med Res Rev 2010;30(1):67–101. DOI: 10.1002/med.20165. PMID: 19536865.
28. Trevino V., Tadesse M.G., Vannucci M. et al. Analysis of normal-tumour tissue interaction in tumours: prediction of prostate cancer features from the molecular profile of adjacent normal cells. PLoS One 2011;6(3):e16492. DOI: 10.1371/journal.pone.0016492. PMID: 21479216.
29. Breen K.J., O’Neill A., Murphy L. et al. Investigating the role of the IGF axis as a predictor of biochemical recurrence in prostate cancer patients post-surgery. Prostate 2017;77(12):1288–300. DOI: 10.1002/pros.23389. PMID: 28726241.
30. Chang C.F., Pao J.B., Yu C.C. et al. Common variants in IGF1 pathway genes and clinical outcomes after radical prostatectomy. Ann Surg Oncol 2013;20(7):2446–52. DOI: 10.1245/s10434-013-2884-y. PMID: 23397154.
Рецензия
Для цитирования:
Шкурников М.Ю., Алексеев Б.Я. Ассоциация экспрессии генов рецепторов фактора роста тромбоцитов альфа и бета (PDGFRA и PDGFRB) с биохимическим рецидивом рака предстательной железы после радикальной простатэктомии. Онкоурология. 2017;13(4):45-50. https://doi.org/10.17650/1726-9776-2017-13-4-45-50
For citation:
Shkurnikov M.Yu., Alekseev B.Ya. Expression of platelet-derived growth factor alpha and beta genes PDGFRA and PDGFRB associated with biochemical recurrence of prostate cancer after radical prostatectomy. Cancer Urology. 2017;13(4):45-50. https://doi.org/10.17650/1726-9776-2017-13-4-45-50